nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—Paget's disease of bone—bone cancer	0.762	1	CtDrD
Zoledronate—ABCC1—Epirubicin—bone cancer	0.0767	0.489	CbGbCtD
Zoledronate—ABCC1—Doxorubicin—bone cancer	0.0408	0.26	CbGbCtD
Zoledronate—ABCC1—Methotrexate—bone cancer	0.0395	0.252	CbGbCtD
Zoledronate—FDPS—jaw skeleton—bone cancer	0.00497	0.248	CbGeAlD
Zoledronate—FDPS—periosteum—bone cancer	0.00375	0.187	CbGeAlD
Zoledronate—CA2—periosteum—bone cancer	0.00195	0.0973	CbGeAlD
Zoledronate—GGPS1—connective tissue—bone cancer	0.00142	0.0709	CbGeAlD
Zoledronate—GGPS1—tendon—bone cancer	0.000975	0.0487	CbGeAlD
Zoledronate—GGPS1—bone marrow—bone cancer	0.000945	0.0472	CbGeAlD
Zoledronate—GGPS1—spinal cord—bone cancer	0.00094	0.047	CbGeAlD
Zoledronate—Risedronate—PTGS2—bone cancer	0.000765	0.529	CrCbGaD
Zoledronate—Clodronate—PTGS2—bone cancer	0.000682	0.471	CrCbGaD
Zoledronate—CA12—connective tissue—bone cancer	0.000661	0.033	CbGeAlD
Zoledronate—FDPS—connective tissue—bone cancer	0.000654	0.0327	CbGeAlD
Zoledronate—CA14—tendon—bone cancer	0.000583	0.0291	CbGeAlD
Zoledronate—CA14—spinal cord—bone cancer	0.000562	0.0281	CbGeAlD
Zoledronate—FDPS—tendon—bone cancer	0.000449	0.0225	CbGeAlD
Zoledronate—FDPS—bone marrow—bone cancer	0.000435	0.0218	CbGeAlD
Zoledronate—FDPS—spinal cord—bone cancer	0.000434	0.0217	CbGeAlD
Zoledronate—CA2—connective tissue—bone cancer	0.00034	0.017	CbGeAlD
Zoledronate—ABCC1—tendon—bone cancer	0.000261	0.013	CbGeAlD
Zoledronate—CA2—tendon—bone cancer	0.000233	0.0117	CbGeAlD
Zoledronate—CA2—bone marrow—bone cancer	0.000226	0.0113	CbGeAlD
Zoledronate—CA2—spinal cord—bone cancer	0.000225	0.0112	CbGeAlD
Zoledronate—Infestation NOS—Epirubicin—bone cancer	0.000108	0.00183	CcSEcCtD
Zoledronate—Infestation—Epirubicin—bone cancer	0.000108	0.00183	CcSEcCtD
Zoledronate—Agranulocytosis—Methotrexate—bone cancer	0.000108	0.00182	CcSEcCtD
Zoledronate—Pancytopenia—Doxorubicin—bone cancer	0.000107	0.0018	CcSEcCtD
Zoledronate—Renal failure—Epirubicin—bone cancer	0.000107	0.00179	CcSEcCtD
Zoledronate—Body temperature increased—Cisplatin—bone cancer	0.000107	0.00179	CcSEcCtD
Zoledronate—Stomatitis—Epirubicin—bone cancer	0.000106	0.00178	CcSEcCtD
Zoledronate—Conjunctivitis—Epirubicin—bone cancer	0.000105	0.00177	CcSEcCtD
Zoledronate—Urinary tract infection—Epirubicin—bone cancer	0.000105	0.00177	CcSEcCtD
Zoledronate—Neutropenia—Doxorubicin—bone cancer	0.000105	0.00177	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000105	0.00176	CcSEcCtD
Zoledronate—Pollakiuria—Doxorubicin—bone cancer	0.000104	0.00175	CcSEcCtD
Zoledronate—Haematuria—Epirubicin—bone cancer	0.000103	0.00174	CcSEcCtD
Zoledronate—Urinary tract disorder—Methotrexate—bone cancer	0.000103	0.00173	CcSEcCtD
Zoledronate—Weight increased—Doxorubicin—bone cancer	0.000102	0.00172	CcSEcCtD
Zoledronate—Urethral disorder—Methotrexate—bone cancer	0.000102	0.00172	CcSEcCtD
Zoledronate—Weight decreased—Doxorubicin—bone cancer	0.000102	0.00171	CcSEcCtD
Zoledronate—Agranulocytosis—Epirubicin—bone cancer	0.000101	0.0017	CcSEcCtD
Zoledronate—Infestation NOS—Doxorubicin—bone cancer	0.0001	0.00169	CcSEcCtD
Zoledronate—Infestation—Doxorubicin—bone cancer	0.0001	0.00169	CcSEcCtD
Zoledronate—Hypersensitivity—Cisplatin—bone cancer	9.93e-05	0.00167	CcSEcCtD
Zoledronate—Bradycardia—Epirubicin—bone cancer	9.91e-05	0.00167	CcSEcCtD
Zoledronate—Renal failure—Doxorubicin—bone cancer	9.87e-05	0.00166	CcSEcCtD
Zoledronate—Stomatitis—Doxorubicin—bone cancer	9.78e-05	0.00165	CcSEcCtD
Zoledronate—Conjunctivitis—Doxorubicin—bone cancer	9.76e-05	0.00164	CcSEcCtD
Zoledronate—Urinary tract infection—Doxorubicin—bone cancer	9.76e-05	0.00164	CcSEcCtD
Zoledronate—Eye disorder—Methotrexate—bone cancer	9.73e-05	0.00164	CcSEcCtD
Zoledronate—Hypoaesthesia—Epirubicin—bone cancer	9.69e-05	0.00163	CcSEcCtD
Zoledronate—Asthenia—Cisplatin—bone cancer	9.67e-05	0.00163	CcSEcCtD
Zoledronate—Cardiac disorder—Methotrexate—bone cancer	9.66e-05	0.00163	CcSEcCtD
Zoledronate—Urinary tract disorder—Epirubicin—bone cancer	9.62e-05	0.00162	CcSEcCtD
Zoledronate—Oedema peripheral—Epirubicin—bone cancer	9.59e-05	0.00161	CcSEcCtD
Zoledronate—Haematuria—Doxorubicin—bone cancer	9.57e-05	0.00161	CcSEcCtD
Zoledronate—Connective tissue disorder—Epirubicin—bone cancer	9.57e-05	0.00161	CcSEcCtD
Zoledronate—Urethral disorder—Epirubicin—bone cancer	9.55e-05	0.00161	CcSEcCtD
Zoledronate—Angiopathy—Methotrexate—bone cancer	9.44e-05	0.00159	CcSEcCtD
Zoledronate—Immune system disorder—Methotrexate—bone cancer	9.4e-05	0.00158	CcSEcCtD
Zoledronate—Mediastinal disorder—Methotrexate—bone cancer	9.38e-05	0.00158	CcSEcCtD
Zoledronate—Agranulocytosis—Doxorubicin—bone cancer	9.37e-05	0.00158	CcSEcCtD
Zoledronate—Chills—Methotrexate—bone cancer	9.34e-05	0.00157	CcSEcCtD
Zoledronate—Diarrhoea—Cisplatin—bone cancer	9.22e-05	0.00155	CcSEcCtD
Zoledronate—Alopecia—Methotrexate—bone cancer	9.2e-05	0.00155	CcSEcCtD
Zoledronate—Bradycardia—Doxorubicin—bone cancer	9.17e-05	0.00154	CcSEcCtD
Zoledronate—Mental disorder—Methotrexate—bone cancer	9.12e-05	0.00153	CcSEcCtD
Zoledronate—Eye disorder—Epirubicin—bone cancer	9.1e-05	0.00153	CcSEcCtD
Zoledronate—Erythema—Methotrexate—bone cancer	9.06e-05	0.00152	CcSEcCtD
Zoledronate—Malnutrition—Methotrexate—bone cancer	9.06e-05	0.00152	CcSEcCtD
Zoledronate—Flushing—Epirubicin—bone cancer	9.04e-05	0.00152	CcSEcCtD
Zoledronate—Cardiac disorder—Epirubicin—bone cancer	9.04e-05	0.00152	CcSEcCtD
Zoledronate—Hypoaesthesia—Doxorubicin—bone cancer	8.97e-05	0.00151	CcSEcCtD
Zoledronate—Urinary tract disorder—Doxorubicin—bone cancer	8.9e-05	0.0015	CcSEcCtD
Zoledronate—Oedema peripheral—Doxorubicin—bone cancer	8.88e-05	0.00149	CcSEcCtD
Zoledronate—Dysgeusia—Methotrexate—bone cancer	8.87e-05	0.00149	CcSEcCtD
Zoledronate—Connective tissue disorder—Doxorubicin—bone cancer	8.86e-05	0.00149	CcSEcCtD
Zoledronate—Angiopathy—Epirubicin—bone cancer	8.84e-05	0.00149	CcSEcCtD
Zoledronate—Urethral disorder—Doxorubicin—bone cancer	8.83e-05	0.00149	CcSEcCtD
Zoledronate—Immune system disorder—Epirubicin—bone cancer	8.8e-05	0.00148	CcSEcCtD
Zoledronate—Mediastinal disorder—Epirubicin—bone cancer	8.78e-05	0.00148	CcSEcCtD
Zoledronate—Back pain—Methotrexate—bone cancer	8.76e-05	0.00147	CcSEcCtD
Zoledronate—Chills—Epirubicin—bone cancer	8.74e-05	0.00147	CcSEcCtD
Zoledronate—Arrhythmia—Epirubicin—bone cancer	8.7e-05	0.00146	CcSEcCtD
Zoledronate—Alopecia—Epirubicin—bone cancer	8.61e-05	0.00145	CcSEcCtD
Zoledronate—Vomiting—Cisplatin—bone cancer	8.57e-05	0.00144	CcSEcCtD
Zoledronate—Vision blurred—Methotrexate—bone cancer	8.54e-05	0.00144	CcSEcCtD
Zoledronate—Mental disorder—Epirubicin—bone cancer	8.53e-05	0.00144	CcSEcCtD
Zoledronate—Rash—Cisplatin—bone cancer	8.5e-05	0.00143	CcSEcCtD
Zoledronate—Dermatitis—Cisplatin—bone cancer	8.49e-05	0.00143	CcSEcCtD
Zoledronate—Malnutrition—Epirubicin—bone cancer	8.48e-05	0.00143	CcSEcCtD
Zoledronate—Erythema—Epirubicin—bone cancer	8.48e-05	0.00143	CcSEcCtD
Zoledronate—Eye disorder—Doxorubicin—bone cancer	8.42e-05	0.00142	CcSEcCtD
Zoledronate—Ill-defined disorder—Methotrexate—bone cancer	8.41e-05	0.00141	CcSEcCtD
Zoledronate—Anaemia—Methotrexate—bone cancer	8.37e-05	0.00141	CcSEcCtD
Zoledronate—Flushing—Doxorubicin—bone cancer	8.36e-05	0.00141	CcSEcCtD
Zoledronate—Cardiac disorder—Doxorubicin—bone cancer	8.36e-05	0.00141	CcSEcCtD
Zoledronate—Dysgeusia—Epirubicin—bone cancer	8.3e-05	0.0014	CcSEcCtD
Zoledronate—Back pain—Epirubicin—bone cancer	8.2e-05	0.00138	CcSEcCtD
Zoledronate—Angiopathy—Doxorubicin—bone cancer	8.18e-05	0.00138	CcSEcCtD
Zoledronate—Malaise—Methotrexate—bone cancer	8.17e-05	0.00137	CcSEcCtD
Zoledronate—Muscle spasms—Epirubicin—bone cancer	8.15e-05	0.00137	CcSEcCtD
Zoledronate—Immune system disorder—Doxorubicin—bone cancer	8.14e-05	0.00137	CcSEcCtD
Zoledronate—Vertigo—Methotrexate—bone cancer	8.14e-05	0.00137	CcSEcCtD
Zoledronate—Mediastinal disorder—Doxorubicin—bone cancer	8.12e-05	0.00137	CcSEcCtD
Zoledronate—Leukopenia—Methotrexate—bone cancer	8.11e-05	0.00136	CcSEcCtD
Zoledronate—Chills—Doxorubicin—bone cancer	8.09e-05	0.00136	CcSEcCtD
Zoledronate—Arrhythmia—Doxorubicin—bone cancer	8.05e-05	0.00135	CcSEcCtD
Zoledronate—Nausea—Cisplatin—bone cancer	8e-05	0.00135	CcSEcCtD
Zoledronate—Vision blurred—Epirubicin—bone cancer	7.99e-05	0.00134	CcSEcCtD
Zoledronate—Alopecia—Doxorubicin—bone cancer	7.96e-05	0.00134	CcSEcCtD
Zoledronate—Cough—Methotrexate—bone cancer	7.91e-05	0.00133	CcSEcCtD
Zoledronate—Mental disorder—Doxorubicin—bone cancer	7.9e-05	0.00133	CcSEcCtD
Zoledronate—Ill-defined disorder—Epirubicin—bone cancer	7.87e-05	0.00132	CcSEcCtD
Zoledronate—Convulsion—Methotrexate—bone cancer	7.85e-05	0.00132	CcSEcCtD
Zoledronate—Erythema—Doxorubicin—bone cancer	7.84e-05	0.00132	CcSEcCtD
Zoledronate—Malnutrition—Doxorubicin—bone cancer	7.84e-05	0.00132	CcSEcCtD
Zoledronate—Anaemia—Epirubicin—bone cancer	7.84e-05	0.00132	CcSEcCtD
Zoledronate—Agitation—Epirubicin—bone cancer	7.79e-05	0.00131	CcSEcCtD
Zoledronate—Arthralgia—Methotrexate—bone cancer	7.71e-05	0.0013	CcSEcCtD
Zoledronate—Myalgia—Methotrexate—bone cancer	7.71e-05	0.0013	CcSEcCtD
Zoledronate—Chest pain—Methotrexate—bone cancer	7.71e-05	0.0013	CcSEcCtD
Zoledronate—Dysgeusia—Doxorubicin—bone cancer	7.68e-05	0.00129	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.66e-05	0.00129	CcSEcCtD
Zoledronate—Malaise—Epirubicin—bone cancer	7.65e-05	0.00129	CcSEcCtD
Zoledronate—Discomfort—Methotrexate—bone cancer	7.62e-05	0.00128	CcSEcCtD
Zoledronate—Vertigo—Epirubicin—bone cancer	7.62e-05	0.00128	CcSEcCtD
Zoledronate—Syncope—Epirubicin—bone cancer	7.6e-05	0.00128	CcSEcCtD
Zoledronate—Leukopenia—Epirubicin—bone cancer	7.59e-05	0.00128	CcSEcCtD
Zoledronate—Back pain—Doxorubicin—bone cancer	7.59e-05	0.00128	CcSEcCtD
Zoledronate—Muscle spasms—Doxorubicin—bone cancer	7.54e-05	0.00127	CcSEcCtD
Zoledronate—Palpitations—Epirubicin—bone cancer	7.49e-05	0.00126	CcSEcCtD
Zoledronate—Confusional state—Methotrexate—bone cancer	7.46e-05	0.00125	CcSEcCtD
Zoledronate—Loss of consciousness—Epirubicin—bone cancer	7.45e-05	0.00125	CcSEcCtD
Zoledronate—Cough—Epirubicin—bone cancer	7.4e-05	0.00124	CcSEcCtD
Zoledronate—Anaphylactic shock—Methotrexate—bone cancer	7.39e-05	0.00124	CcSEcCtD
Zoledronate—Vision blurred—Doxorubicin—bone cancer	7.39e-05	0.00124	CcSEcCtD
Zoledronate—Convulsion—Epirubicin—bone cancer	7.35e-05	0.00124	CcSEcCtD
Zoledronate—Infection—Methotrexate—bone cancer	7.35e-05	0.00124	CcSEcCtD
Zoledronate—Hypertension—Epirubicin—bone cancer	7.32e-05	0.00123	CcSEcCtD
Zoledronate—Ill-defined disorder—Doxorubicin—bone cancer	7.28e-05	0.00122	CcSEcCtD
Zoledronate—Nervous system disorder—Methotrexate—bone cancer	7.25e-05	0.00122	CcSEcCtD
Zoledronate—Anaemia—Doxorubicin—bone cancer	7.25e-05	0.00122	CcSEcCtD
Zoledronate—Thrombocytopenia—Methotrexate—bone cancer	7.24e-05	0.00122	CcSEcCtD
Zoledronate—Myalgia—Epirubicin—bone cancer	7.22e-05	0.00121	CcSEcCtD
Zoledronate—Arthralgia—Epirubicin—bone cancer	7.22e-05	0.00121	CcSEcCtD
Zoledronate—Chest pain—Epirubicin—bone cancer	7.22e-05	0.00121	CcSEcCtD
Zoledronate—Agitation—Doxorubicin—bone cancer	7.21e-05	0.00121	CcSEcCtD
Zoledronate—Anxiety—Epirubicin—bone cancer	7.19e-05	0.00121	CcSEcCtD
Zoledronate—Skin disorder—Methotrexate—bone cancer	7.18e-05	0.00121	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	7.17e-05	0.00121	CcSEcCtD
Zoledronate—Hyperhidrosis—Methotrexate—bone cancer	7.15e-05	0.0012	CcSEcCtD
Zoledronate—Discomfort—Epirubicin—bone cancer	7.13e-05	0.0012	CcSEcCtD
Zoledronate—Malaise—Doxorubicin—bone cancer	7.07e-05	0.00119	CcSEcCtD
Zoledronate—Dry mouth—Epirubicin—bone cancer	7.06e-05	0.00119	CcSEcCtD
Zoledronate—Vertigo—Doxorubicin—bone cancer	7.05e-05	0.00119	CcSEcCtD
Zoledronate—Anorexia—Methotrexate—bone cancer	7.05e-05	0.00119	CcSEcCtD
Zoledronate—Syncope—Doxorubicin—bone cancer	7.04e-05	0.00118	CcSEcCtD
Zoledronate—Leukopenia—Doxorubicin—bone cancer	7.02e-05	0.00118	CcSEcCtD
Zoledronate—Confusional state—Epirubicin—bone cancer	6.98e-05	0.00117	CcSEcCtD
Zoledronate—Palpitations—Doxorubicin—bone cancer	6.93e-05	0.00117	CcSEcCtD
Zoledronate—Oedema—Epirubicin—bone cancer	6.92e-05	0.00116	CcSEcCtD
Zoledronate—Anaphylactic shock—Epirubicin—bone cancer	6.92e-05	0.00116	CcSEcCtD
Zoledronate—Hypotension—Methotrexate—bone cancer	6.91e-05	0.00116	CcSEcCtD
Zoledronate—Loss of consciousness—Doxorubicin—bone cancer	6.89e-05	0.00116	CcSEcCtD
Zoledronate—Infection—Epirubicin—bone cancer	6.87e-05	0.00116	CcSEcCtD
Zoledronate—Cough—Doxorubicin—bone cancer	6.85e-05	0.00115	CcSEcCtD
Zoledronate—Shock—Epirubicin—bone cancer	6.81e-05	0.00115	CcSEcCtD
Zoledronate—Convulsion—Doxorubicin—bone cancer	6.8e-05	0.00114	CcSEcCtD
Zoledronate—Nervous system disorder—Epirubicin—bone cancer	6.79e-05	0.00114	CcSEcCtD
Zoledronate—Thrombocytopenia—Epirubicin—bone cancer	6.77e-05	0.00114	CcSEcCtD
Zoledronate—Hypertension—Doxorubicin—bone cancer	6.77e-05	0.00114	CcSEcCtD
Zoledronate—Tachycardia—Epirubicin—bone cancer	6.75e-05	0.00114	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Methotrexate—bone cancer	6.74e-05	0.00113	CcSEcCtD
Zoledronate—Skin disorder—Epirubicin—bone cancer	6.72e-05	0.00113	CcSEcCtD
Zoledronate—Hyperhidrosis—Epirubicin—bone cancer	6.69e-05	0.00113	CcSEcCtD
Zoledronate—Insomnia—Methotrexate—bone cancer	6.69e-05	0.00113	CcSEcCtD
Zoledronate—Arthralgia—Doxorubicin—bone cancer	6.68e-05	0.00112	CcSEcCtD
Zoledronate—Chest pain—Doxorubicin—bone cancer	6.68e-05	0.00112	CcSEcCtD
Zoledronate—Myalgia—Doxorubicin—bone cancer	6.68e-05	0.00112	CcSEcCtD
Zoledronate—Anxiety—Doxorubicin—bone cancer	6.66e-05	0.00112	CcSEcCtD
Zoledronate—Paraesthesia—Methotrexate—bone cancer	6.64e-05	0.00112	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.63e-05	0.00112	CcSEcCtD
Zoledronate—Discomfort—Doxorubicin—bone cancer	6.6e-05	0.00111	CcSEcCtD
Zoledronate—Anorexia—Epirubicin—bone cancer	6.6e-05	0.00111	CcSEcCtD
Zoledronate—Dyspnoea—Methotrexate—bone cancer	6.59e-05	0.00111	CcSEcCtD
Zoledronate—Somnolence—Methotrexate—bone cancer	6.57e-05	0.00111	CcSEcCtD
Zoledronate—Dry mouth—Doxorubicin—bone cancer	6.53e-05	0.0011	CcSEcCtD
Zoledronate—Dyspepsia—Methotrexate—bone cancer	6.51e-05	0.0011	CcSEcCtD
Zoledronate—Hypotension—Epirubicin—bone cancer	6.47e-05	0.00109	CcSEcCtD
Zoledronate—Confusional state—Doxorubicin—bone cancer	6.46e-05	0.00109	CcSEcCtD
Zoledronate—Decreased appetite—Methotrexate—bone cancer	6.43e-05	0.00108	CcSEcCtD
Zoledronate—Anaphylactic shock—Doxorubicin—bone cancer	6.4e-05	0.00108	CcSEcCtD
Zoledronate—Oedema—Doxorubicin—bone cancer	6.4e-05	0.00108	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Methotrexate—bone cancer	6.38e-05	0.00107	CcSEcCtD
Zoledronate—Fatigue—Methotrexate—bone cancer	6.37e-05	0.00107	CcSEcCtD
Zoledronate—Infection—Doxorubicin—bone cancer	6.36e-05	0.00107	CcSEcCtD
Zoledronate—Pain—Methotrexate—bone cancer	6.32e-05	0.00106	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Epirubicin—bone cancer	6.3e-05	0.00106	CcSEcCtD
Zoledronate—Shock—Doxorubicin—bone cancer	6.3e-05	0.00106	CcSEcCtD
Zoledronate—Nervous system disorder—Doxorubicin—bone cancer	6.28e-05	0.00106	CcSEcCtD
Zoledronate—Thrombocytopenia—Doxorubicin—bone cancer	6.27e-05	0.00105	CcSEcCtD
Zoledronate—Insomnia—Epirubicin—bone cancer	6.26e-05	0.00105	CcSEcCtD
Zoledronate—Tachycardia—Doxorubicin—bone cancer	6.25e-05	0.00105	CcSEcCtD
Zoledronate—Skin disorder—Doxorubicin—bone cancer	6.22e-05	0.00105	CcSEcCtD
Zoledronate—Paraesthesia—Epirubicin—bone cancer	6.21e-05	0.00105	CcSEcCtD
Zoledronate—Hyperhidrosis—Doxorubicin—bone cancer	6.19e-05	0.00104	CcSEcCtD
Zoledronate—Dyspnoea—Epirubicin—bone cancer	6.17e-05	0.00104	CcSEcCtD
Zoledronate—Somnolence—Epirubicin—bone cancer	6.15e-05	0.00104	CcSEcCtD
Zoledronate—Anorexia—Doxorubicin—bone cancer	6.1e-05	0.00103	CcSEcCtD
Zoledronate—Feeling abnormal—Methotrexate—bone cancer	6.09e-05	0.00103	CcSEcCtD
Zoledronate—Dyspepsia—Epirubicin—bone cancer	6.09e-05	0.00102	CcSEcCtD
Zoledronate—Gastrointestinal pain—Methotrexate—bone cancer	6.05e-05	0.00102	CcSEcCtD
Zoledronate—Decreased appetite—Epirubicin—bone cancer	6.02e-05	0.00101	CcSEcCtD
Zoledronate—Hypotension—Doxorubicin—bone cancer	5.98e-05	0.00101	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Epirubicin—bone cancer	5.97e-05	0.00101	CcSEcCtD
Zoledronate—Fatigue—Epirubicin—bone cancer	5.97e-05	0.001	CcSEcCtD
Zoledronate—Constipation—Epirubicin—bone cancer	5.92e-05	0.000996	CcSEcCtD
Zoledronate—Pain—Epirubicin—bone cancer	5.92e-05	0.000996	CcSEcCtD
Zoledronate—Urticaria—Methotrexate—bone cancer	5.87e-05	0.000988	CcSEcCtD
Zoledronate—Abdominal pain—Methotrexate—bone cancer	5.84e-05	0.000983	CcSEcCtD
Zoledronate—Body temperature increased—Methotrexate—bone cancer	5.84e-05	0.000983	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Doxorubicin—bone cancer	5.83e-05	0.000981	CcSEcCtD
Zoledronate—Insomnia—Doxorubicin—bone cancer	5.79e-05	0.000974	CcSEcCtD
Zoledronate—Paraesthesia—Doxorubicin—bone cancer	5.75e-05	0.000967	CcSEcCtD
Zoledronate—Dyspnoea—Doxorubicin—bone cancer	5.71e-05	0.00096	CcSEcCtD
Zoledronate—Feeling abnormal—Epirubicin—bone cancer	5.7e-05	0.000959	CcSEcCtD
Zoledronate—Somnolence—Doxorubicin—bone cancer	5.69e-05	0.000958	CcSEcCtD
Zoledronate—Gastrointestinal pain—Epirubicin—bone cancer	5.66e-05	0.000952	CcSEcCtD
Zoledronate—Dyspepsia—Doxorubicin—bone cancer	5.64e-05	0.000948	CcSEcCtD
Zoledronate—Decreased appetite—Doxorubicin—bone cancer	5.57e-05	0.000936	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Doxorubicin—bone cancer	5.53e-05	0.00093	CcSEcCtD
Zoledronate—Fatigue—Doxorubicin—bone cancer	5.52e-05	0.000929	CcSEcCtD
Zoledronate—Urticaria—Epirubicin—bone cancer	5.5e-05	0.000925	CcSEcCtD
Zoledronate—Pain—Doxorubicin—bone cancer	5.47e-05	0.000921	CcSEcCtD
Zoledronate—Constipation—Doxorubicin—bone cancer	5.47e-05	0.000921	CcSEcCtD
Zoledronate—Body temperature increased—Epirubicin—bone cancer	5.47e-05	0.00092	CcSEcCtD
Zoledronate—Abdominal pain—Epirubicin—bone cancer	5.47e-05	0.00092	CcSEcCtD
Zoledronate—Hypersensitivity—Methotrexate—bone cancer	5.45e-05	0.000917	CcSEcCtD
Zoledronate—Asthenia—Methotrexate—bone cancer	5.3e-05	0.000893	CcSEcCtD
Zoledronate—Feeling abnormal—Doxorubicin—bone cancer	5.28e-05	0.000888	CcSEcCtD
Zoledronate—Gastrointestinal pain—Doxorubicin—bone cancer	5.24e-05	0.000881	CcSEcCtD
Zoledronate—Pruritus—Methotrexate—bone cancer	5.23e-05	0.00088	CcSEcCtD
Zoledronate—Hypersensitivity—Epirubicin—bone cancer	5.1e-05	0.000858	CcSEcCtD
Zoledronate—Urticaria—Doxorubicin—bone cancer	5.09e-05	0.000856	CcSEcCtD
Zoledronate—Body temperature increased—Doxorubicin—bone cancer	5.06e-05	0.000852	CcSEcCtD
Zoledronate—Abdominal pain—Doxorubicin—bone cancer	5.06e-05	0.000852	CcSEcCtD
Zoledronate—Diarrhoea—Methotrexate—bone cancer	5.06e-05	0.000851	CcSEcCtD
Zoledronate—Asthenia—Epirubicin—bone cancer	4.96e-05	0.000835	CcSEcCtD
Zoledronate—Pruritus—Epirubicin—bone cancer	4.9e-05	0.000824	CcSEcCtD
Zoledronate—Dizziness—Methotrexate—bone cancer	4.89e-05	0.000823	CcSEcCtD
Zoledronate—Diarrhoea—Epirubicin—bone cancer	4.73e-05	0.000797	CcSEcCtD
Zoledronate—Hypersensitivity—Doxorubicin—bone cancer	4.72e-05	0.000794	CcSEcCtD
Zoledronate—Vomiting—Methotrexate—bone cancer	4.7e-05	0.000791	CcSEcCtD
Zoledronate—Rash—Methotrexate—bone cancer	4.66e-05	0.000784	CcSEcCtD
Zoledronate—Dermatitis—Methotrexate—bone cancer	4.66e-05	0.000784	CcSEcCtD
Zoledronate—Headache—Methotrexate—bone cancer	4.63e-05	0.000779	CcSEcCtD
Zoledronate—Asthenia—Doxorubicin—bone cancer	4.59e-05	0.000773	CcSEcCtD
Zoledronate—Dizziness—Epirubicin—bone cancer	4.58e-05	0.00077	CcSEcCtD
Zoledronate—Pruritus—Doxorubicin—bone cancer	4.53e-05	0.000762	CcSEcCtD
Zoledronate—Vomiting—Epirubicin—bone cancer	4.4e-05	0.00074	CcSEcCtD
Zoledronate—Nausea—Methotrexate—bone cancer	4.39e-05	0.000739	CcSEcCtD
Zoledronate—Diarrhoea—Doxorubicin—bone cancer	4.38e-05	0.000737	CcSEcCtD
Zoledronate—Rash—Epirubicin—bone cancer	4.36e-05	0.000734	CcSEcCtD
Zoledronate—Dermatitis—Epirubicin—bone cancer	4.36e-05	0.000733	CcSEcCtD
Zoledronate—Headache—Epirubicin—bone cancer	4.33e-05	0.000729	CcSEcCtD
Zoledronate—Dizziness—Doxorubicin—bone cancer	4.23e-05	0.000712	CcSEcCtD
Zoledronate—Nausea—Epirubicin—bone cancer	4.11e-05	0.000692	CcSEcCtD
Zoledronate—Vomiting—Doxorubicin—bone cancer	4.07e-05	0.000685	CcSEcCtD
Zoledronate—Rash—Doxorubicin—bone cancer	4.04e-05	0.000679	CcSEcCtD
Zoledronate—Dermatitis—Doxorubicin—bone cancer	4.03e-05	0.000679	CcSEcCtD
Zoledronate—Headache—Doxorubicin—bone cancer	4.01e-05	0.000675	CcSEcCtD
Zoledronate—Nausea—Doxorubicin—bone cancer	3.8e-05	0.00064	CcSEcCtD
